Therapeutic Solutions International, Inc. (TSOI)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Oct 24, 2025, 4:00 PM EDT
TSOI Revenue
Therapeutic Solutions International had revenue of $19.67K in the quarter ending September 30, 2024, a decrease of -23.56%. This brings the company's revenue in the last twelve months to $85.32K, up 1.89% year-over-year. In the year 2023, Therapeutic Solutions International had annual revenue of $98.99K, down -52.12%.
Revenue (ttm)
85.32K
Revenue Growth
+1.89%
P/S Ratio
0.08
Revenue / Employee
28.44K
Employees
3
Market Cap
7.05K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 98.99K | -107.77K | -52.12% |
| Dec 31, 2022 | 206.77K | 60.81K | 41.66% |
| Dec 31, 2021 | 145.96K | 83.28K | 132.86% |
| Dec 31, 2020 | 62.68K | 35.19K | 127.97% |
| Dec 31, 2019 | 27.50K | 24.01K | 689.18% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Therapeutic Solutions International News
- 6 months ago - Therapeutic Solutions International to Voluntarily Delist - Business Wire
- 1 year ago - Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases - Business Wire
- 1 year ago - Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients - Business Wire
- 1 year ago - Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product - Business Wire
- 1 year ago - Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation - Business Wire
- 1 year ago - Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities - Business Wire
- 1 year ago - Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy - Business Wire
- 1 year ago - Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™ - Business Wire